NYSE:EVMN • US30054Y1073
ChartMill assigns a Buy % Consensus number of 86% to EVMN. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-22 | Oppenheimer | Initiate | Outperform |
| 2026-01-08 | Raymond James | Initiate | Strong Buy |
| 2026-01-06 | HC Wainwright & Co. | Initiate | Buy |
| 2025-12-01 | Leerink Partners | Initiate | Outperform |
| 2025-12-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-12-01 | William Blair | Initiate | Outperform |
| 2025-12-01 | Evercore ISI Group | Initiate | Outperform |
| 2025-12-01 | Morgan Stanley | Initiate | Overweight |
10 analysts have analysed EVMN and the average price target is 39.95 USD. This implies a price increase of 43.29% is expected in the next year compared to the current price of 27.88.
The consensus rating for EVOMMUNE INC (EVMN) is 86 / 100 . This indicates that analysts generally have a positive outlook on the stock.